Juan José Cerezo-Manchado

Creating a genotype-based dosing algorithm for acenocoumarol steady dose

Juan José Cerezo-Manchado, Mario Rosafalco, Ana Isabel Antón et al. · Thrombosis and Haemostasis · 2012 · 32 citations

Medicine, Pharmacokinetics, Pharmacology +15

Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population

María Cerdá, Juan José Cerezo-Manchado, Erik Johansson et al. · Journal of Comparative Effectiveness Research · 2019 · 23 citations

Medicine, Cardiology, Pharmacotherapy +11

Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements

Ana Isabel Antón, Juan José Cerezo-Manchado, José Padilla et al. · PLoS ONE · 2013 · 18 citations · Full text

Life Sciences, Genetics, Pharmacology +13

Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol

Teodoro Iturbe-Hernández, Luis García de Guadiana‐Romualdo, I. Ortega et al. · Drugs in Context · 2020 · 17 citations · Full text

Medicine, Cardiology, Pharmacology +17

Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase Registry

Begoña Navarro-Almenzar, Juan José Cerezo-Manchado, César Caro Martínez et al. · Current Medical Research and Opinion · 2019 · 13 citations

Pharmacy, Cardiology, Pharmacotherapy +17